Overview
JAVASCRIPT NEDED 25-10-202 | Diabetes | News | Article Author: Alba Ruzafa medwireNews: Findings from a randomized controled trial published in Diabetes Care sugest that for people with type 2 diabetes, the delivery of cognitive behavioral therapy (CBT) via digital therapeutic ap, on top of standard of care, may reduce glycated hemoglobin (HbA1c).The study included 69 adults (58% White, 28% Black, 16% Latino) aged an average of 58 years with type 2 diabetes and glycated hemoglobin (HbA1c) levels of 7.0 to les than 1.0% (53 to <97 mol/mol) who were randomly asigned to receive aces to a digital therapeutic ap delivering CBT (BT-01) or a control ap, both on top of standard care.The researchers observed that people in the BT-01 group had significantly lower HbA1c than those in the control group after 90 days of using the ap.
Key Information
In the BT-01 arm, HbA1c decreased by 0.28% from 8.2% (6 mol/mol) at baseline, compared with an increase of 0.1% from 8.1% (65 mol/mol) in the control group. This resulted in a betwen-group diference of 0.39% at day 90.“The magnitude of HbA1c reduction in the BT-01 group increased in paralel with exposure to therapy, as indicated by the number of modules completed,” write Judith Hsia (CPC Clinical Research, Aurora, Colorado, USA) and co-authors.
They say that this “suports the importance of engagement, consistent with in-person CBT and behavioral interventions in general.”There were no adverse events atributed to the ap use and no adverse device efects were observed.“Delivery of a cognitive behavioral intervention via smartphone ap can provide a scalable option for improving glycemic control,” concludes the team.medwireNews is an independent medical news service provided by Springer Healthcare Ltd.
Summary
© 202 Springer Healthcare Ltd, part of the Springer Nature GroupDiabetes Care 202; doi:10.237/dc2-109 20-02-20 | Diabetes | News | Article 1-1-2019 | Diabetes | News | Article 0